You are a researcher at a small biotech company and your company has just obtain
ID: 177363 • Letter: Y
Question
You are a researcher at a small biotech company and your company has just obtained the license for use of a human GENOMIC DNA fragment putatively encoding a potentially novel protein, which is thought to regulate p53, the known tumor supressor protein. The scientists who originally cloned this GENE fragment HDM5 "claim" that HDM5 shares 90% DNA sequence homology with one of the HDM2 genes (refer to the review Levine & Oren, 2009). They propose that HDM5 may have HDM2-like properties and may be involved in regulating cell proliferation, and thus a good target to potentially develop as a cancer therapy. Your company has asked you to characterize the gene and gene products, as well as to provide an opinion as to its potential human therapeutic uses.
1. Before proceeding, you wish to know whether this gene is actually expressed in humans (your target market for therapeutic development). Describe, in detail, 2 efficient experimental approaches to answer this question. Discuss whether your proposed methods measure synthesis or accumulation of the product.
Explanation / Answer
1) The first Experimental Approach is by inserting The Desired Gene Inside The Mouse Which is being Affected Orr mutated By Tumour P53 Gene. If in That Case Our Desired gene Is Expressed It will Produce A Desired Protein And Will Supress The Mutated P53 Gene Thus Inhibiting Cancer Formation In Mouse. .
2) in the second case we can do for a human trails where it can be inserted n Human Artificial chromosome plasmid and that plasmid can be transferred to the human body where it can be expressed and can be checked where protein can be formed..
That protein can be searched in the cytoplasm of the cell where there are expressed. This can result in formation of Inclusion Bodies ie. Small aggregates of protein hence can be inferred that whter accumulated or not.
Related Questions
Navigate
Integrity-first tutoring: explanations and feedback only — we do not complete graded work. Learn more.